Literature DB >> 11173641

Polychondritis Terminating in Eosinophilic Leukemia.

Judit Várkonyi1, Lajos Jakab, Attila Zalatnay, Péter Nagy, Rita Vámoss, Tamás Szombathy.   

Abstract

We report here on a patient presenting with Relapsing Polychondritis (RP) two years before the diagnosis of Myelodysplasia (MDS) terminating in Eosinophilic Leukemia (EoL). The evolution of RP several etiology of RP in this patient. The terminal development of EoL in our case is assumed to represent clonal evolution caused by a second mutagenic event. The existence of autoimmune skin disorders in both the patient and his offspring (vitiligo and subacute cutaneous lupus erythematosus, respectively) implies that the coexistence of MDS and RP may have been caused by a functional disturbance of the immune system.

Entities:  

Year:  1997        PMID: 11173641     DOI: 10.1007/bf02907809

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  18 in total

1.  Erythroid progenitors in mouse bone marrow detected by macroscopic colony formation in culture.

Authors:  N N Iscove; F Sieber
Journal:  Exp Hematol       Date:  1975-01       Impact factor: 3.084

2.  Relapsing polychondritis: autoimmunity to type II collagen and treatment with cyclosporin A.

Authors:  A Anstey; S Mayou; K Morgan; R B Clague; D D Munro
Journal:  Br J Dermatol       Date:  1991-12       Impact factor: 9.302

Review 3.  Relapsing polychondritis: prospective study of 23 patients and a review of the literature.

Authors:  L P McAdam; M A O'Hanlan; R Bluestone; C M Pearson
Journal:  Medicine (Baltimore)       Date:  1976-05       Impact factor: 1.889

4.  Myelodysplastic syndrome with eosinophilia in bone marrow. Gunma Haematology Study Group.

Authors:  T Matsushima; H Murakami; M Sawamura; J Tamura; T Sakura; M Matsumoto; H Hirabayashi; S Miyawaki; S Simano; S Sato
Journal:  Br J Haematol       Date:  1993-08       Impact factor: 6.998

5.  Acute eosinophilic leukemia in a patient with preexistent myelodysplastic syndrome.

Authors:  M Murakawa; T Shibuya; S Taniguchi; K Nakashima; T Okamura; M Harada; Y Niho
Journal:  Acta Haematol       Date:  1991       Impact factor: 2.195

6.  Myelodysplastic syndrome associated with relapsing polychondritis: unusual transformation from refractory anemia to chronic myelomonocytic leukemia.

Authors:  T Shirota; O Hayashi; H Uchida; N Tonozuka; N Sakai; H Itoh
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

Review 7.  Refractory anaemia with hypereosinophilia and clonal abnormal metaphases detected only in the neutrophilic granulopoietic series.

Authors:  A Pérez-Losada; S Woessner; F Solé; L Florensa; A Grañena
Journal:  Acta Haematol       Date:  1994       Impact factor: 2.195

8.  Relapsing polychondritis: a paraneoplastic syndrome associated with myelodysplastic syndromes.

Authors:  K Van Besien; G Tricot; R Hoffman
Journal:  Am J Hematol       Date:  1992-05       Impact factor: 10.047

Review 9.  Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality.

Authors:  M L Malbrain; H Van den Bergh; P Zachée
Journal:  Br J Haematol       Date:  1996-01       Impact factor: 6.998

10.  Bone marrow pathology in relapsing polychondritis: high frequency of myelodysplastic syndromes.

Authors:  L Diebold; G Rauh; K Jäger; U Löhrs
Journal:  Br J Haematol       Date:  1995-04       Impact factor: 6.998

View more
  2 in total

1.  Total hearing loss and blindness caused by relapsing polychondritis and myelodysplastic syndrome.

Authors:  Bozena Coha; Ljubica Fustar-Preradovic; Sandra Sekelj; Alen Sekelj
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-07-17       Impact factor: 2.503

2.  A nationwide study of the epidemiology of relapsing polychondritis.

Authors:  Anna Horváth; Nóra Páll; Katalin Molnár; Tamás Kováts; György Surján; Tamás Vicsek; Péter Pollner
Journal:  Clin Epidemiol       Date:  2016-06-23       Impact factor: 4.790

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.